Propensity for subsequent distant metastasis in head and neck squamous-cell carcinoma (HNSCC) was analysed using 186 primary tumours from patients initially treated by surgery that developed (M) or did not develop (NM) metastases as the first recurrent event. Transcriptome (Affymetrix HGU133_Plus2, QRT-PCR) and arraycomparative genomic hybridization data were collected. Non-supervised hierarchical clustering based on Affymetrix data distinguished tumours differing in pathological differentiation, and identified associated functional changes. Propensity for metastasis was not associated with these subgroups. Using QRT-PCR data we identified a four-gene model (PSMD10, HSD17B12, FLOT2 and KRT17) that predicts M/NM status with 77% success in a separate 79-sample validation group of HNSCC samples. This prediction is independent of clinical criteria (age, lymph node status, stage, differentiation and localization). The most significantly altered transcripts in M versus NM were significantly associated to metastasis-related functions, including adhesion, mobility and cell survival. Several genomic modifications were significantly associated with M/NM status (most notably gains at 4q11-22 and Xq12-28; losses at 11q14-24 and 17q11 losses) and partly linked to transcription modifications. This work yields a basis for the development of prognostic molecular signatures, markers and therapeutic targets for HNSCC metastasis.
Introduction
There are various aetiological factors for head and neck squamous-cell carcinoma (HNSCC), including alcohol consumption with smoking and human papillomavirus (HPV) infection, for our patient population (Applebaum et al., 2007; Hashibe et al., 2007) . Survival is still poor (5-year survival 30-50%), mainly due to relapse, metastasis or second cancer (Forastiere et al., 2001; Le Tourneau et al., 2005) . The anatomic location and TNM staging guide treatment selection, but patients with similar tumour characteristics differ in their clinical outcome. Our aim is to identify, in primary tumours, molecular signatures that predict the subsequent development of distant metastases in patients treated with complete surgical resection and adjuvant therapy. Furthermore, we want to study the still poorly understood biological processes that predispose human tumours to the development of metastases, and to define targets for therapy.
Our previous study, using large-scale validated differential display, identified 820 transcripts that were differentially expressed between tumours and normal tissue, about 10% of which differed between tumours that did (M) or did not (NM) develop metastasis as the first recurrence event (Carles et al., 2006) . A subsequent study, with 28 tumours and Affymetrix U95A arrays (Affymetrix, Santa Clara, CA, USA) detected 164 transcripts whose levels differed significantly between N and NM tumours, but we did not find changes that could be used to predict N/NM status in independent samples (Cromer et al., 2004) . Signatures of poor prognosis and metastasis have been identified in other larger scale studies (review: Nguyen and Massague, 2007) . We now report a larger study, using more samples (186) and RNA variables (Affymetrix HG-U133 plus 2.0 GeneChips), and we have included an analysis of genomic changes (IntegraChip 4.4K bacterial artificial chromosomes (BAC) comparative genomic hybridisation (CGH) arrays, array-CGH (aCGH)). Using unsupervised analysis, we defined intrinsic groups that correspond to pathological differentiation. Using QRT-PCR-validated RNA levels and a training group, we have defined a four-gene model that predicts future distant metastasis with 77% success in an independent validation group. We have identified genomic and transcriptomic changes that are significantly different in primary tumours with dissimilar M/NM status. These findings are useful for the development of prospective signatures of metastasis, and for the understanding of biological processes that predispose to the development of metastases in patients with HNSCC.
Results

Classification of tumours
The global differences between the transcriptomes of the HNSCC tumours may result from metastatic propensity, or other clinical or biological features. To detect these 'intrinsic' features, we performed unsupervised hierarchical classification as already described (Boyault et al., 2007) . We studied extensively the robustness of the topologies (series of dendrograms) obtained under different conditions: three distinct agglomerative clustering methods, various thresholds for variance based unsupervised gene selection, resampling and addition of Gaussian noise to the data. We found that the sample partitions that yielded between two to four sample groups were very reproducible (Supplementary Table 1) and identified a consensus partition of four groups (Supplementary Figure 1) . For illustrative purposes, we selected a representative sample dendrogram that was most related to the consensus partition ( Figure 1 ). Using Fisher's exact tests we found that these four major clusters (C1-C4) were not significantly associated with stage, localization, metastasis-free survival (Figure 1 ), or any of the other characteristics of the tumours analysed (data not shown). However, C1-C3 were significantly associated with degree of differentiation, corresponding to well (C1), moderately (C2) and poorly (C3) differentiated tumours. C4 was not association with any of the characteristics analysed. These results suggest that pathological differentiation has the biggest effect on the overall differences in transcription of the tumours.
To get a better understanding of the molecular determinants of the intrinsic groups, we analysed the 449-gene list (548 probe sets) that was used to generate the four clusters in the representative dendrogram shown in Figure 1 . Unsupervised cluster analysis was used to segregate the genes into six gene groups (a-f; Figure 1 ). Using hypergeometric tests we determined if there was an enrichment of particular biological pathways and functions in the six gene groups (see Supplementary Material and methods). This allowed us to characterize the gene clusters a-f by the most significantly associated gene ontology (GO; Ashburner et al., 2000) terms and pathways (Supplementary Table  2 ), which included cell differentiation, extracellular matrix organization, tissue development, adhesion and immune response (Figure 1 ). We then characterized each sample group (C1-C4), according to the genes specifically up/downregulated within this group and their associated GO terms and pathways. For example, poorly differentiated tumours (C3) are characterized by upregulation in gene cluster a, which is significantly associated with cell motility. Sample group C4 is associated with upregulation of genes encoding for proteins related to muscle structure and function (approximately half of the 59 significant GO terms that are enriched in the gene cluster f, Figure 1 ; see the GO analysis Supplementary Table 2 sheet 2, and the genes in cluster f in Supplementary Table 2 sheet 1). This is a clue to the origin of cluster C4.
To further analyse the biological functions associated with pathologically defined differentiation (as opposed to the intrinsic groups defined by unsupervised classification) we performed a supervised analysis between the tumours classified according to pathological differentiation (Table 1; Supplementary Table 3) . Using 1-way ANOVA (Po0.01) and pairwise Wilcoxon tests (Po0.001) we established three lists of genes (a total of 835 genes) that were significantly differentially expressed between at least two of the three clinically defined groups (Supplementary Table 4) . As expected, a number of the genes (50) involved in the unsupervised clustering ( Figure 1 ) were among the 835 significant genes obtained from the supervised analysis. QRT-PCR validation of seven genes confirmed that there is a gradient of expression between poorly to well-differentiated tumours (Figure 2 ; in general there was a very high correlation between the Affymetrix and QRT-PCR, data not shown). These genes were chosen as representative genes that are differentially expressed in tumours according to their pathologically defined differentiation status, and due to the potential importance of the encoded proteins for cell differentiation (see Supplementary Table 5 , column H, for a brief description). Further analysis of the genes that are differentially expressed between the tumours could provide insights into the molecular events that are related to pathological differentiation of HNSCC.
Four-gene model predicting future metastasis in HNSCC that is independent of clinical variables Given that metastasis was not associated with any of the intrinsic HNSCC subgroups, we set out to identify a molecular signature that is predictive of developing future metastasis irrespective of differentiation status and/or other clinical variables, and that could be employed in a clinical environment using quantitative PCR. Of the initial 186 patients, 142 (50M and 92 NM) were used for transcriptome, genome and bioinformatics analysis as they had a minimal follow-up period of 36 months (Table 1; Supplementary Table 3 Table 5 ; Supplementary Material and methods). The DNA variables did not add predictive power. Subsequently, RNAs from 134 tumours were quantified by QRT-PCR (73 'Affymetrix' þ 61 additional samples; Table 2 ). From Cox analysis using a training group (55 samples, S1 0 ), we identified a four-gene model (PSMD10, HSD17B12, FLOT2 and KRT17; Table 3 ). We analysed its performance in an independent validation group that was not used for selection (79 samples, S2 0 ). It predicted M/NM class membership with an overall success rate of 77% (74% sensitivity (M predicted as M) and 78% specificity (NM predicted as NM)). Using Cox proportional hazard univariate analysis, we showed that the four-gene model was highly associated with the development of metastasis (hazard ratio (HR) of 6.5; (95% confidence interval (CI) 2.4-18.1; P ¼ 0.0003; Table 4) ). Moreover, the four-gene model performed better than other prognostic factors, including lymph node status, pathological grade and localization. Using multivariate analysis, we showed that the four-gene model retained significant predictive value when adjusted for all the other clinicopathological variables together (Table 4) Table 6 ). Pathological stage and localization also retain their predictive values when adjusted for all the other variables, whether the four-gene model was included or not (Table 4) . Kaplan-Meier curves (Figure 3 ; Supplementary Figure 2 ) were used to visualize event-free survival (metastasis) with time of the groups selected by different criteria. The four-gene model successfully selected groups with differences in event-free survival with: the validation group (A), the whole population (B), patients that were NO/N1 or N2 þ (C), and patients with pathological stage oIV or ¼ IV (D). The four-gene model performed favourably in comparison with the other clinical criteria considered individually ( Supplementary Figure 2A) , including node presence (B), stage (C), localization (D), differentiation (E) or age (F). These results show that the four-gene model outperforms and is independent from other clinical variables in predicting the development of metastasis. (Table) . The clinical parameters with the lowest P-values are shown in parenthesis in the Table. (b) Gene dendrogram (left) using the 2.5% (548) most varying probe-sets and heat map of gene expression in the samples. The gene dendrogram was partitioned (dark black line) arbitrarily to define six gene-cluster groups (a-f, dark blue to red rectangles). Enriched gene ontology (GO) categories (black, Supplementary Table 2 sheet 2) and corresponding genes (blue) of clusters a-f are shown on the right. The genes in the clusters a-f are listed in Supplementary Table 2 sheet 1, and those shown on the right are selected examples. Abbreviations: aCGH, array-comparative genomic hybridization; HPV, human papillomavirus; na, not annotated. Overviews are given for the patients selected for the CIT study from the CPS tumour collection and the subsequent subgroups used for data generation (measures) with transcriptome (Affymetrix) and genome (CGH) arrays, and bioinformatics analysis (analysis). The term 'M+NM' refers to the total number of patients (metastatic (M) plus the non-metastatic (NM)) for the indicated characteristic. The groups (S) used for the analysis of the array (S1-S3) and QRT-PCR (S1 0 , S2 0 ) data are described in Material and methods. The values are the number of patients or time (age (years) and clinical follow up (months)).
Transcriptomic description of metastatic propensity
In order to explore the molecular mechanisms behind the development of distant metastasis in HNSCC, we identified 614 genes with significantly altered expression levels in M relative to NM using Cox univariate tests on the Affymetrix data from 81 samples (41M versus 40 NM, Po0.01;. Supplementary Table 7) . We selected and validated the differential expression of 22 genes using QRT-PCR analysis of the 134 samples ( Figure 4 ). The 22 genes were selected as representative genes that would validate the microarray analysis, and also by subjective criteria such as encoding proteins that could be important for metastasis (apoptosis, cell-cycle regulation, cell interactions, oncogenesis, poor prognosis and signalling pathways involved in metastasis; see Discussion). We analysed the 614 genes for association with particular biological pathways and functions (Supplementary Material and Methods). The 614 M/ NM genes were found to encode, in particular, proteins associated with major functional categories and pathways that could be important for metastasis (RNA processing, development/differentiation, transcription regulation, cell signalling, adhesion/motility, proliferation and metabolism; Table 5; Supplementary Table 7) . These factors might confer propensity to metastasize to primary tumours.
Chromosome alterations associated with metastatic propensity and correlation with the transcriptome HNSCC is known to be associated with extensive chromosomal alterations. We searched for chromosomal alterations associated with the propensity to metastasize using aCGH with 74 HNSCCs. As expected, we found numerous chromosome alterations in the overall population (Supplementary Figure 3) that have been observed previously (Baudis and Cleary, 2001; Gollin, 2001; Jarvinen et al., 2006; gains: 3q, 5p, 7q, 8q, 11q13; losses: 3p, 8p, 9p, 11q14-24, 13q, 18q, 21q) . We also detected a number of additional alterations (gains at 1q, 12p and Xq and losses at 4p, 7q, 11q, 17p, 19p and Xp; Supplementary Table 8) .
As genomic alterations could be responsible for the altered expression of genes, we analysed the level of gene expression in M versus NM along the chromosomes using windows of 5 Â 10 6 base pairs and steps of 2 Â 10 Table 7 ). These genes, that are both dysregulated and located in altered genomic regions, classify M and NM with a 76.8% success rate (data not shown), which is not better that the four-gene model (77% success). A number of these regions also have DNA copy number alterations associated with metastatic propensity (for example, 4q21;q22, 11q23.1 and Xq22.1; Figure 5 ; Supplementary Tables 7 and 8) . Of interest, one of the genes in the four-gene model, PSMD10, is located in a zone of genes overexpressed in M at Xq22 ( Figure 6a , black line; individual genes are indicated with red triangles). This zone corresponds to a chromosomal region that also has a gain in DNA copy Figure 6a , solid blue line; 6b shows in detail the X chromosome aCGH data, with statistically significant regions in yellow). Overexpression is not observed in M samples without genomic gain (dotted black line), indicating that increased expression is linked to gene copy number. We confirmed by QRT-PCR that genes in this region are overexpressed in M samples (Figure 6a , see gene names). We also found zones of deregulated genes that are not associated with changes in DNA copy number associated with metastasis (examples: 1q, 12p, 18p,q and 19p; Figure 5 ; Supplementary Tables 7 and 8 ) suggesting other mechanisms of metastasis-related gene regulation.
Discussion
One aim of this study was to develop a predictive signature for patients who, after complete surgical resection as a first treatment and adjuvant therapy, will develop metastases as the first recurrence in a 36-month follow-up. HPV positive samples were eliminated from this study because we found that they had distinct changes at the RNA and DNA levels, and thus deserved to be treated separately (recently confirmed by Ragin et al., 2006; Slebos et al., 2006; Schlecht et al., 2007) . Unsupervised analysis of transcripts that varied most between the samples led to the identification of intrinsic groups related to histological differentiation. There was no correlation between the intrinsic groups and M/NM status. The genes that define the different intrinsic groups, as well as the genes that are differentially expressed between different pathological-differentiation groups, are predominantly involved in potentially relevant functions. The poorly differentiated tumours (C1 and C2) overexpress genes involved in embryonic development, cell adhesion, differentiation, motility and extracellular matrix, whereas well-differentiated tumours (C3) overexpress genes involved in metabolism, epithelial cell differentiation and anti-apoptosis. The Figure 3 Kaplan-Meier curves of event free survival (future distant metastasis) of the groups selected with the four-gene model, starting with (a) the validation group (n ¼ 79, S2 0 , group 1 ¼ at risk), (b) the whole population (n ¼ 134, S1 0 þ S2 0 ), (c) subgroups of the whole population formed with N0/N1 and N2 and (d) subgroups of the whole population formed with pathological stages less than and equal to IV. Censored events are marked under the curves on the graphs. The w 2 (Chisq) and log-rank P-values are shown. The tables below the figures give, at 10-month intervals, the numbers of patients remaining at risk in the groups (a, 0 ¼ predicted as NM,
fourth intrinsic group (C4) was not significantly associated with any clinical characteristic, but was weakly association with localization to the oral cavity. C4 expresses genes involved in muscle differentiation. It remains to be seen whether C4 will be identified in analyses of additional samples, and to determine its origin.
We report a four-gene predictor based on QRT-PCR, which is, to our knowledge, the first predictor of distant metastasis in HNSCC. It is a significant predictor of metastasis, even when combined with the other criteria used for prognosis (age, stage, differentiation and localization) and is independent of HNSCC intrinsic subgroups suggesting that it could contribute to clinical decision making. However, it would not replace them, because other current clinical criteria (age, stage, lymph node involvement and localization) remain significant when the four-gene model is used for prediction. Further studies will be required before the four-gene model could be ready for clinical decision making (Ludwig and Weinstein, 2005; Glas et al., 2006; Kaklamani and Gradishar, 2006; Ioannidis, 2007) . Translating molecular profiles to the clinic generally requires assay development, demonstration and validation of predictive performance, provision of independent information beyond classical predictors, accumulation of evidence, demonstration of clinical efficacy, and then integration into clinical practise (see Ioannidis, 2007) . We have developed the assay, demonstrated its predictive performance and validated its performance on an independent group of patients. A new prospective study on a larger population is now ongoing, which consists of studying about 200 new patients and following their clinical outcome over the next three years. Further validation using patients recruited in other hospitals, through collaborations at the national and international levels, is planned. Globally, a number of molecular profiles are being standardized, particularly for breast cancer and for some haematological malignancies. Many others are in the exploratory phase (Ioannidis, 2007) .
This study extends and confirms our previous work; 17 of the original 133 'descriptors' of M/MN status were also identified in this study, 16/17 with concordant relative expression (Cromer et al., 2004; Supplementary Table 9) ). There was little overlap with genes identified in other reports on HNSCC and some key studies on other tumours (Supplementary Table 9 ), as might be expected from the distinct nature and aims of this study. In our previous work, we were unable to identify genes that could be used to predict whether the patients would develop distant metastasis following treatment. A related study reached the same conclusion (Braakhuis et al., 2006) . The previous unsuccessful studies were of smaller scale, which could account for the inability to find predictor gene models. We increased both the number of transcripts and patients analysed by approximately fourfold, and added an analysis of 4.4K BAC probes on CGH arrays. Furthermore, we used RNA levels quantitated by QRT-PCR in the selection procedure. The transcriptome variables alone contributed to the four-gene model. There are genome variables that are significantly different between M and NM The table shows the gene ontology (GO) biological pathways with the encompassed GO term identifiers (GO-id), the total number of genes englobed by the GO terms, the numbers in the lists of upregulated (a) and downregulated (b) genes in relation to metastasis (M vs NM), the significance levels of the hypergeometric tests (P-value), the GO terms and the symbols of the deregulated genes in the lists.
patients, but none were selected during model building. The genomic analysis was less exhaustive than the transcriptome analysis, because the resolution of the BAC arrays is smaller (55K transcripts versus 4.4K genomic regions). In addition, the RNA and DNA variables may be partially redundant, because we identified zones of altered transcription in genomic regions that are also altered. In fact, about 5% of the top M-associated genes are clustered in amplified genomic regions also associated with M, suggesting that these events are linked and redundant. Transcripts may be more informative than genomic alterations for other reasons. In particular, many transcripts that are clustered in genomic zones and are associated with M (about 50% of the most significant genes) map to genomic regions where the alterations are not associated with M, or are unaltered. There are many mechanisms that could account for the zonal effects on transcription of neighbouring genes, including coregulation of related clusters of genes, and epigenetic modifications that affect large regions of the genome (Esteller, 2007) .
The four-gene model efficiently selected M tumours on an independent validation group of 79 samples. Previous studies of HNSCC have identified genes associated with lymph node metastasis, which is also an independent predictor of distant metastasis (Chung et al., 2004; Roepman et al., 2005) . Our predictor has a significant HR in N þ patients (5.2 (1.9-17.8), P ¼ 0.0015), showing that it is an independent marker. There are few genes in common between this report and other studies with potentially related aims (lymph node metastasis (Roepman et al., 2005; Zhou et al., 2006) or with paradigm work (Ramaswamy et al., 2003; Glas et al., 2006) . In fact, there is also a lack of similarity between the other studies (Supplementary Table 9 ). This difference in the genes used for prediction does not detract from the validity of the models, whose purpose is to predict events in independent samples (Dupuy and Simon, 2007) .
The predictor genes in the four-gene model (PSMD10, HSD17B12, FLOT2 and KRT17) code for proteins with highly relevant biological functions. PSMD10 is an oncoprotein, regulates pRb and p53, and is part of the regulatory 19S proteasome particle (Dawson et al., 2006) . HSD17B12 may play a role in breast cancer progression (Song et al., 2006) , and could be a target for endocrine-disrupting cancer treatment from its role in the conversion of E1 to E2 (Sanderson, 2006) . FLOT2 is a cell-surface protein that regulates key functions for metastasis, including GPCR signalling, actin cytoskeleton structure, invasion, cell-matrix adhesion and spreading (Babuke and Tikkanen, 2007) . KRT17 is an unusual cytokeratin. Mutations in KRT17 lead to Jackson-Lawler type pachyonychia congenita and steatocystoma multiplex, and KRT17-null mice develop alopecia. It is rapidly induced by wounding of stratified epithelia, and regulates cell growth and size (van de Rijn et al., 2002; Kaklamani and Gradishar, 2006) . KRT17 may to be a marker of certain epithelial stem cells (Gu and Coulombe, 2007) .
The genes comprising the four-gene model were selected by model building with bioinformatics, which can generate many signatures of similar performance, and small variations in the model-building group can produce a number of models with similar performances (Roepman et al., 2006) . Apparently, the genes that we have selected for the four-gene model could have key functions related to metastatic propensity, suggesting they are related to the underlying biological mechanisms and could be developed as targets for therapy. Genes that have been identified in related studies could be components of the same pathways, or could belong to other pathways. Further analysis will be required to investigate these possibilities.
Additional biologically important functions could be represented in the more extensive list of 'descriptor' genes, whose expression differs between the M and NM tumours. This list was found to be enriched in genes that encode for proteins with expected relevant functions, that in M tumours could lead to increased RNA/DNA processing, transcription and Wnt signalling, and decreased differentiation, adhesion and proliferation (see Supplementary Table 7) . Amongst the 22 QRT-PCR-validated descriptor genes (Figure 4) , we found a downregulation in M tumours of genes that encode for proteins involved in apoptosis (CASP1, DAPK3, IL18, PPP2R1B), negative regulation of the cell cycle (DST) and cell interactions (COL17A1), and upregulation of genes encoding proteins involved in oncogenesis and poor prognosis (MYCN) and Wnt signalling (LRP6). Interestingly, the Wnt pathway has great potential for cancer therapeutic design (Barker and Clevers, 2006) . Recent studies have shown that metastasis is a distinct function that is not necessarily linked to the classical properties of oncogenes and tumour suppressor genes (cell division, apoptosis, and so on). This is an emerging field (Nguyen and Massague, 2007) and the HNSCC M/ NM 'descriptor' is presumable enriched in metastasis genes. The roles of these genes need to be investigated in model systems, including the use of HNSCC cell lines in cell culture and mice, assaying for cell movement, invasion, growth in suspension and metastasis. . The y axis is the log2-ratio of prometastasis versus metastasis-free patients. The solid black line represents the ratio M/NM of the median expression values obtained from all probe sets in the 21K list that are mapped within a 8 megabase genomic region from M samples having the gain shown grey (n ¼ 9) and NM samples without the gain (n ¼ 34). The dotted black line represents the median of probe sets for pro-metastasis samples with no gain (n ¼ 29) versus the median of metastasis-free samples having no gain (n ¼ 34). The blue solid line is the smoothed log2-ratio of the CGH data from prometastasis samples having the gain (n ¼ 9) versus that of the metastasis-free samples having no gain (n ¼ 34). Cox univariate significant genes are labelled with pink and green triangles, which correspond to over-and underexpressed in prometastasis versus metastasis-free samples, respectively. Genes used for M/NM prediction (Table 3) An intriguing finding is that several genes associated with M (BEX1, BEX2, ZNF6, NGFRAP1L1, GPRASP2) are clustered on chromosome Xq21-22, whose chromosome gain is also associated with M ( Figure 6 ; Supplementary Table 7 ), indicating that they are important for metastasis. BEX 1 regulates nerve growth-factor signalling, neuronal differentiation, and cell-cycle progression (Vilar et al., 2006) . The BEX1 gene is epigenetically silenced by promoter hypermethylation in malignant gliomas. It is involved in sensitivity to chemotherapy-induced apoptosis and in tumorigenesis (Foltz et al., 2006) . BEX2 interacts with LMO2 and regulates transcription (Han et al., 2005) ZNF6 could be a Zn finger transcription factor. NGFRAP1L1 has no known function, but is possible involved in apoptosis. GPRASP2 interacts with Gprotein coupled receptors and may have a role in signalling (Simonin et al., 2004) . This is the first description of this alteration, and merits further investigation, for example in relationship to X-chromosome inactivation in females.
In addition to the genomic alterations associated with M/NM status, we observed many others that were not significantly associated with future metastasis. Some have been described before (Baudis and Cleary, 2001; Gollin, 2001; Jarvinen et al., 2006) , others have not been reported. The genomic events not associated with metastasis might be driven by additional biological processes involved in the development of tumours, or may be indirect consequences of genomic instability. Functional studies in model systems will be required to investigate these possibilities.
Our results constitute a rich foundation for future work. The intrinsic groups were apparently selected on the basis of a molecular description of differentiation. This molecular signature may be useful in refining classification of pathological differentiation compared to clinical-histological criteria. Molecular classification could increase the diagnostic value of differentiation in the clinic. Another group of tumours, identifiable by HPV infection and other molecular criteria (manuscript in preparation), may have different prognosis and may benefit from different treatment modalities, such as HPV therapeutic vaccines currently under development. The genome and transcriptome changes may indicate potentially interesting metastatic functions, and the Xq21-22 region may be of particular interest for further investigation. Most interestingly, we have found a 'predictor' (the four-gene model) that can be used to identify individuals whose primary HNSCC exhibit high metastatic potential. This molecular signature may accurately predict clinical outcome and may help to improve therapeutic management of patients with HNSCC in the future.
Materials and methods
Unsupervised classification, gene set enrichment analysis, statistics See Supplementary Materials and methods.
Patients and samples
Tumour samples came from the Biological Collection of the Centre Paul Strauss. Patients were operated for primary HNSCC between 1988 and 2003. Tumour samples were collected at the time of surgery, with the patient's informed consent. A fragment was taken near the advancing edge of the primary tumour (avoiding its necrotic centre), immediately frozen in liquid nitrogen and stored at À80 1C. The rest of the tumour was fixed in 6% buffered formaldehyde and embedded in paraffin for histopathological analysis. The UICC TNM system (Sobin and Fleming, 1997) was used for tumour-nodemetastasis staging. Histological examination of sections adjacent to each tumour fragment showed that 60-80% were tumour cells.
A total of 186 samples were included in transcriptome and genome array analysis. The criteria for inclusion were: tumour localization (oral cavity, tongue, oropharynx and hypopharynx), no clinically evident distant metastases by conventional clinical and diagnostic radiological examinations (computed tomography), surgical resection was the first treatment, and at least 3 mm of the surgical margins were histologically tumour free. The patients were treated post surgery with adjuvant radiotherapy (RX, the majority); several also had combined chemotherapy (the minority). HPV was detected in 19 patients, and will be reported elsewhere. 142 patients were grouped according to whether, during the clinical follow-up of at least 36 months, they developed distant metastases as the first recurrence (M) or did not (NM). Patients without RX therapy were included only if they did not develop any recurrence (that is, NM patients), and the few cases with combined radiotherapy and chemotherapy only if they developed metastases (that is, M). For tumour characteristics, treatment, clinical follow up and sample group distribution, see Table 1 and  Supplementary Table 3. 'Pathological differentiation' is the status of each tumour established by microscopic assessment by a pathologist. HNSCC is classically categorized into three degrees of differentiation, according to the amount of 'keratinization': well differentiated >75%, moderately differentiated 25-75%, poorly differentiated o25%.
Data
See EBI ArrayExpress (E-TABM-302; www.ebi.ac.uk/arrayex press).
Gene expression and array-comparative genome hybridization Except when indicated, transcriptome and aCGH analyses used either an assortment of R system software (v1.9. 0) packages and Bioconductor (V1.1.1), or original R code.
Nucleic acid preparation Total RNA was extracted using the RNAeasy kit (Qiagen, Courtaboeuf, France) with DNase I treatment. DNA was extracted with phenol-chloroform using standard procedures. Their integrity was verified on an Agilent 2100 Bioanalyser (Agilent Technologies, Palo Alto, CA, USA).
Microarray analyses Three micrograms of total RNA (10 mg cRNA per hybridization) from 98 tumour samples was amplified, labelled following the manufacturer's one-cycle target labelling protocol (http://www.affymetrix. com), and hybridized to HG-U133 plus 2.0 Affymetrix GeneChip arrays (Affymetrix; GeneChip Fluidics Station 400). The chips were scanned with the Affymetrix GeneChip Scanner 3000 and images analysed using GCOS 1.4. Raw feature data were normalized and log 2 intensity expression summary values for each probe set were calculated using robust multi-array average (RMA, package affy V1.4.32; Irizarry et al., 2003) . Probe sets corresponding to control genes or having a '_x_' annotation were masked, yielding a total of 50 406 probe sets available for further analyses. We then calculated the 80th percentile intensity value for each of the 50 406 probe sets and eliminated those with a value less than or equal to 15 intensity units (non-log and after RMA normalization). This yielded 21 906 probe sets for further analysis.
QRT-PCR A total of 182 HNSCC samples were analysed for 59 genes, of which 31 were for metastasis prediction, 22 for metastasis characterization and 7 for differentiation (Supplementary Table 5 ). Three micrograms of total RNA was reverse transcribed using the High Capacity Archive kit and random hexamers (Applied Biosystems, Courtaboeuf, France). cDNA quality was assessed using R18S quantification by real-time PCR (coefficient of variation 7% for the entire series). One microliter of cDNA (2 ng of reverse transcribed RNA) was analysed in duplicate using TaqMan Low Density Arrays and the ABI PRISM 7900HT System (Applied Biosystems). The variability of duplicates was less than 5% in each measure; therefore we used the mean of duplicate measures to estimate the level of gene expression. Gene expression was normalized to the average Ct values of two internal controls, R18S and RPLP0 (Vandesompele et al., 2002; GeNorm software) .
aCGH A total of 94 DNA samples, from amongst the 98 samples studied with Affymetrix arrays, were analysed with IntegraChip (IntegraGen, Evry, France) aCGH microarrays containing 4434 BACs. The control was mixed blood DNA from 20 healthy females used at the same concentration. Smoothed, normalized log2-ratio values were partitioned into three groups: gain, no change or loss (GNL). Recurrent or consensus variables were defined as variables that occurred in more than 2 of the 94 samples (see Supplementary Materials and Methods for more details).
Prediction analysis Initial selection was based on univariate and multivariate Cox analyses (survival R package v2.26) of Affymetrix gene chip variables using 81 samples, divided into three groups: training group S1 (20M and 20 NM samples), training group S2 (10M and 10 NM samples) and a validation group S3 (11M and 10 NM samples). As an initial approach we combined the expression data obtained using Affymetrix gene chips with the array CGH datasets (normalized log-ratios and GNL status, see below). We performed Cox univariate tests using the S1 group of samples and the three different data sets (21K Affymetrix data set, the 4K aCGH log 2 -ratio values and the 2.2K GNL aCGH values). Using a P-value cut-off of 0.025 we obtained 566, 107 and 92 variables, respectively. A binning approach was applied by clustering (average linkage, 1-Pearson correlation coefficient (r)) independently, each resulting S1 data set, cutting the variable dendrogram (r ¼ 0.65) and selecting the variable from each cluster that yielded the lowest Cox univariate log-rank P-value. A combined data set was constructed of the selected variables (81 total variables: 61 Affymetrix probe sets, 14 aCGH log 2 -ratios and 6 aCGH GNL variables). To build the multi-gene (1-4 genes) predictors, Cox multivariate models were constructed using two bottom-up methods: (1) with or (2) without possibility to go backward (that is, drop a gene selected at a previous step). Each of the variables was used to build a Cox model; this model was used to predict class membership for S1 based on the resulting score from each sample (using a zero as a threshold, a threshold that was used in all groups). The model was applied to S2 group of samples. The highest average success rate from the two sets was used to choose the top variable. All combinations of the other variables in the combined data set and the chosen variable (that is, twovariable combination) were then used to construct a two-gene predictor. The two-variable predictor yielding the highest average success rate (for S1 and S2) was chosen and so on until the best four-variable predictor was identified. One-to fourgene models with a success rate lower than 80% were eliminated. The six top models (top model for 2-4 genes (n ¼ 3 models) and for each of the two-step methods) were then applied to the S3 group. This approach yielded two top predictors (total of five genes), one for each step method. To determine the top predictor using the QRT-PCR data of the entire sample population, we included 26 additional genes with the 5 genes mentioned above (a total of 31 genes). The 26 genes were chosen because they were amongst the top 30 genes (ranked using the univariate log-rank P-value) that were characterized (had HUGO gene symbols) and could be analysed with the transcript-matched ABI assay-on-demand. Of the 81 samples studied using Affymetrix arrays, 8 yielded poor quality QRT-PCR 18S control data. Of the remaining 73 samples, the S1 and S2 groups were combined to form the S1 0 training group (n ¼ 55 samples) and were used for gene selection (Cox univariate test with log-rank Po0.05) and model construction using the QRT-PCR data. Eighteen S3 samples (that had not been used for selection) were combined with sixty-one additional samples not studied using Affymetrix arrays to form the S2 0 validation group (n ¼ 79 samples; Table 2 ).
Analysis of expression profiles along the chromosome Chromosome positions of the Affymetrix U133 plus 2.0 probe sets were obtaining from Affymetrix (NetAffx analysis centre, http://www.affymetrix.com/analysis/index.affx) and ENSEMBL (http://www.ensembl.org/index.html). Using a window of 5 Â 10 6 bases and 2 Â 10 6 -base steps along the chromosome we calculated a local s.d. based on the distribution of the expression values obtained for the non-metastasis samples for each window along the chromosome. We then calculated the P-value of local enrichment (Fisher's exact test) of probe sets that, in the M samples, were two s.d. above or below the median expression value for that window of the non-metastasis samples. Windows containing less than five probe sets were not considered. A total of 1523 genomic regions were assessed. We also employed GSEA ( (Subramanian et al., 2005) ) using cytoband localization to define gene sets to assess enrichment associated with metastasis.
Supervised analyses Cox univariate and Wilcoxon nonparametric tests (R survival v2.26. package, and GeneSpring GX 7.3 (Agilent Technologies), respectively) were used to define the differentially expressed gene lists with a significance level of each univariate test of Po0.01, unless otherwise indicated. We have calculated a local FDR estimate for our test results using R package q-value from B Efron and R Tibshirani. For gene ontology and biological pathways analyses we used a hypergeometric test to measure the association between a gene (feature) list and a biological pathway or a gene ontology term (see Supplementary Materials and Methods for more details). 
